GlaxoSmithKline to Make a Bid for Human Genome Sciences?

Britain’s Daily Mail is reporting rumors that GlaxoSmithKline (NYSE:GSK) may make a bid for Human Genome Sciences (NASDAQ:HGSI).

Following is some information on these companies’ stock price performance:

  • Human Genome Sciences (NASDAQ:HGSI): The shares recently traded at $12.97, up $1.72, or 15.56%, on the day.  The shares have traded in a 52-week range of $10.40 to $30.15 and its market capitalization is $2.47 billion.   About the company: Human Genome Sciences, Inc. researches and develops proprietary pharmaceutical and diagnostic products.  The Company’s products predict, prevent, detect, treat, and cure disease based on the discovery of human and microbial genes.
  • GlaxoSmithKline (NYSE:GSK): The shares recently traded at $42.98, down $0.25, or 0.58%, on the day.  The shares have traded in a 52-week range of $36.28 to $45.34 and its market capitalization is $109.82 billion.   About the company: GlaxoSmithKline plc is a research-based pharmaceutical group that develops, manufactures and markets vaccines, prescription and over-the-counter medicines, as well as health-related consumer products.  The Group, which also provides laboratory testing and disease management services, specializes in treatments for respiratory, central nervous system, gastro-intestinal and genetic disorders.

(Note: Selected financial data are sourced from Google Finance.  All data are assumed to be accurate.)

Advantage: Check out our interactive stock charts, fundamentals, Twitter stream, and more >>

Earnings: Johnson & Johnson Earnings Cheat Sheet: Shrinking Margins for Fifth Consecutive Quarter, but Net Income Rises>>

More from The Cheat Sheet